TAG Policy Brief: Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-down
TAG announces the launch of its latest policy brief: Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-down .
As the Access to COVID-19 Tools Accelerator (ACT-A) and other stakeholders consider market interventions to support the development of rapid diagnostic tests for COVID-19 and to accelerate access to these tests in low- and middle-income countries, the 2012 buy-down of Cepheid’s Xpert MTB/RIF tuberculosis (TB) test provides helpful lessons learned.
TAG’s timely brief examines the background and unexpected consequences of the Xpert MTB/RIF buy-down; applies lessons learned to the ongoing development of COVID-19 diagnostic tests and efforts to scale up access to these tests; and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.
Aimed at global health actors, this brief calls for market intervention agreements for COVID-19 diagnostics to include conditions that promote transparency, competition, COGS+ pricing models, and volume-based price adjustments; and that ensure commitment to equitable allocation based on need rather than country income and ability to pay.
Contact Us: Treatment Action Group, 90 Broad Street, Suite 2503, New York, New York 10004, 212-253-7922. communications@treatmentactiongroup.org. TAG fights for life-saving information and care for people living with, and at risk for, HIV, TB, and HCV. Please consider supporting this work by making a donation today.